“Key Trends in US Biopharma/Medtech Investing”

March 31st (Thurs), 2016
1:00 – 5:00 PM
Yale Club of New York


1:00-1:30 PM Lunch and Networking  

1:30-1:40 PM Opening Remarks 

DoHyun Cho, PhD

CEO and President, W Medical Strategy Group / Chairman, New York Health Forum

1:40-2:30 PM Session 1
Biopharma / Medtech Funding Trends and Investment Landscape 


Joe McMenamin, MD, JD, Executive Vice President, WMSG (Moderator)
Katya Hancock, Director of Strategic Partnerships, StartUp Health
Sean Drake, Managing Director, Stony Lonesome Group LLC

The success of biopharma and medtech companies is dependent upon outside sources of capital to fund the long and costly process of bringing a new therapies to the market. Over the last decade, multiple factors to the industry have had a large impact on the availability of capital. This session examines the current state of biopharma/medtech financing and the factors that have led to the current financing environment and highlights how venture capitals, private equity funds, investment banks and established biopharmaceutical companies have adapted their investment strategies in light of these factors.

2:30-3:20 PM Session 2 
The Key Factors to Raising Capital: What Will Attract Investors? 


Kimberly Ha, Senior Director, FTI Consulting (Moderator)
Norman Yun, Managing Director, H. C. Wainwright & Co.
Vincent Liu, PhD, Managing Director, Chief US Representative, Fosun Pharma

Biopharma/Medtech market is currently booming and year 2016 is expected to be an exciting year for the industry. On the other hand however, there are growing concerns from analysts and investors who question about the long-term sustainability of the market which led to hesitation on placing investments. Investors are becoming less interested in IPOs and are instead turning to less risky investments. In this panel, in-depth discussion will take place on trends and dynamics of current biopharma/medtech industry investment.

3:20 -3:40 PM Networking Break

3:40- 4:30 PM Session 3 
New Breed of Contributors: Alternative Biopharma/Medtech Financing 


Tony Chen, CEO, PrimeVax Immuno-Oncology, Inc (Moderator)
Frank Borchetta, CEO & Co-Founder, Repairogen Corporation
Imran Babar, Senior Associate, OrbiMed LLC
Karen Carr, Regional Development Officer, Gateway for Cancer Research

Disease foundations, private donors, non-for-profit organizations created to support initiatives that answer the needs for development of new therapies. These newer sources of capital added to the traditional ones, are expanding the spectrum of healthcare financing.  Join this panel to hear about the new trend and matrix of alternative healthcare finance.


4:30-4:40 PM Award Ceremony

4:40 PM- Closing

5th New York Health Forum, we invited top venture capitalists, investment banks, hedge funds, granting organizations and placement agencies. Aslo, we invited leading biopharma/medtech companies including but not limited to Pfizer, Merck, BMS, Celgene, Amgen, Vertex, Daichii-Sankyo, Green Cross, Stryker, Medtronic, and etc.